Geron Corporation (GERN): Price and Financial Metrics
GERN Price/Volume Stats
| Current price | $3.69 | 52-week high | $4.05 |
| Prev. close | $3.73 | 52-week low | $1.64 |
| Day low | $3.55 | Volume | 8,226,200 |
| Day high | $3.84 | Avg. volume | 11,242,304 |
| 50-day MA | $2.72 | Dividend yield | N/A |
| 200-day MA | $2.38 | Market Cap | 2.02B |
GERN Stock Price Chart Interactive Chart >
Geron Corporation (GERN) Company Bio
Geron Corporation focuses on the development of telomerase inhibitor, imetelstat, for treating hematologic myeloid malignancies. The company was founded in 1990 and is based in Menlo Park, California.
Latest GERN News From Around the Web
Below are the latest news stories about GERON CORP that investors may wish to consider to help them evaluate GERN as an investment opportunity.
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)FOSTER CITY, Calif., December 21, 2023--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggregate of 417,490 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company. |
Geron (GERN) Upgraded to Buy: Here's WhyGeron (GERN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
Kodiak Sciences Inc. (KOD) Up 43.6% Since Last Earnings Report: Can It Continue?Kodiak Sciences Inc. (KOD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
Geron Announces IMerge Phase 3 Presentations at ASH Highlighting Significant Durability of Transfusion Independence and Breadth of Effect Across MDS Subgroups with Imetelstat in Lower Risk MDSFOSTER CITY, Calif., December 11, 2023--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced presentations of data from its IMerge Phase 3 clinical trial evaluating first-in-class investigational telomerase inhibitor imetelstat in patients with lower risk myelodysplastic syndromes (MDS), as well as population analysis of claims data in lower risk MDS. The data were presented at the American Society of Hematology (ASH) Annual Meeting, taking place fro |
Recent uptick might appease Geron Corporation (NASDAQ:GERN) institutional owners after losing 13% over the past yearKey Insights Significantly high institutional ownership implies Geron's stock price is sensitive to their trading... |
GERN Price Returns
| 1-mo | 10.81% |
| 3-mo | 95.24% |
| 6-mo | 108.47% |
| 1-year | 38.20% |
| 3-year | 149.32% |
| 5-year | 92.19% |
| YTD | 74.88% |
| 2023 | -12.81% |
| 2022 | 98.36% |
| 2021 | -23.27% |
| 2020 | 16.91% |
| 2019 | 36.00% |
Continue Researching GERN
Want to do more research on Geron Corp's stock and its price? Try the links below:Geron Corp (GERN) Stock Price | Nasdaq
Geron Corp (GERN) Stock Quote, History and News - Yahoo Finance
Geron Corp (GERN) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...